

# Thomas Szekeres

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9515017/publications.pdf>

Version: 2024-02-01

141  
papers

4,917  
citations

101543

36  
h-index

110387

64  
g-index

145  
all docs

145  
docs citations

145  
times ranked

6753  
citing authors

#	ARTICLE	IF	CITATIONS
1	Proteinuria in Deceased Kidney Transplant Donors for Prediction of Chronic Lesions in Pretransplant Biopsies: A Prospective Observational Study. <i>Transplantation</i> , 2022, Publish Ahead of Print, .	1.0	2
2	Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease. <i>Digestive and Liver Disease</i> , 2021, 53, 345-352.	0.9	0
3	The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes. <i>Hepatology International</i> , 2021, 15, 1160-1173.	4.2	12
4	NT-proBNP in young healthy adults undergoing non-cardiac surgery. <i>Clinical Biochemistry</i> , 2021, 96, 38-42.	1.9	4
5	Cirrhosis-Associated RAS-Inflammation-Coagulation Axis Anomalies: Parallels to Severe COVID-19. <i>Journal of Personalized Medicine</i> , 2021, 11, 1264.	2.5	10
6	A Multidisciplinary Intervention in Childhood Obesity Acutely Improves Insulin Resistance and Inflammatory Markers Independent From Body Composition. <i>Frontiers in Pediatrics</i> , 2020, 8, 52.	1.9	7
7	Proteomics-Enriched Prediction Model for Poor Neurologic Outcome in Cardiac Arrest Survivors*. <i>Critical Care Medicine</i> , 2020, 48, 167-175.	0.9	16
8	Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication. <i>AIDS Patient Care and STDs</i> , 2019, 33, 197-206.	2.5	10
9	A Sex-Specific Analysis of the Predictive Value of Troponin I and T in Patients With and Without Diabetes Mellitus After Successful Coronary Intervention. <i>Frontiers in Endocrinology</i> , 2019, 10, 105.	3.5	6
10	Galic Acid Improves Health-Associated Biochemical Parameters and Prevents Oxidative Damage of DNA in Type 2 Diabetes Patients: Results of a Placebo-Controlled Pilot Study. <i>Molecular Nutrition and Food Research</i> , 2018, 62, 1700482.	3.3	42
11	Bone Effects of Binge Alcohol Drinking Using Prepubescent Pigs as a Model. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 2123-2135.	2.4	9
12	Thiosemicarbazone derivatives, thiazolyl hydrazones, effectively inhibit leukemic tumor cell growth: Down-regulation of ribonucleotide reductase activity and synergism with arabinofuranosylcytosine. <i>Food and Chemical Toxicology</i> , 2017, 108, 53-62.	3.6	12
13	Involvement of UDP-Glucuronosyltransferases and Sulfotransferases in the Excretion and Tissue Distribution of Resveratrol in Mice. <i>Nutrients</i> , 2017, 9, 1347.	4.1	41
14	Investigation of the Antiproliferative Properties of Natural Sesquiterpenes from <i>Artemisia asiatica</i> and <i>Onopordum acanthium</i> on HL-60 Cells in Vitro. <i>International Journal of Molecular Sciences</i> , 2016, 17, 83.	4.1	17
15	12(S)-HETE increases intracellular Ca <sup>2+</sup> in lymph-endothelial cells disrupting their barrier function in vitro; stabilization by clinical drugs impairing calcium supply. <i>Cancer Letters</i> , 2016, 380, 174-183.	7.2	18
16	Impact of xanthohumol (a prenylated flavonoid from hops) on DNA stability and other health-related biochemical parameters: Results of human intervention trials. <i>Molecular Nutrition and Food Research</i> , 2016, 60, 773-786.	3.3	32
17	A resveratrol analog termed 3,3,4,4,5,5-hexahydroxy- <i>trans</i> -stilbene is a potent HIV-1 inhibitor. <i>Journal of Medical Virology</i> , 2015, 87, 2054-2060.	5.0	14
18	Vemurafenib Resistance Signature by Proteome Analysis Offers New Strategies and Rational Therapeutic Concepts. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 757-768.	4.1	27

#	ARTICLE	IF	CITATIONS
19	Epigallocatechin gallate, ellagic acid, and rosmarinic acid perturb dNTP pools and inhibit de novo DNA synthesis and proliferation of human HL-60 promyelocytic leukemia cells: Synergism with arabinofuranosylcytosine. <i>Phytomedicine</i> , 2015, 22, 213-222.	5.3	32
20	The germacranolide sesquiterpene lactone neurolenin B of the medicinal plant <i>Neurolaena lobata</i> (L.) R.Br. ex Cass inhibits NPM/ALK-driven cell expansion and NF- $\kappa$ B-driven tumour intravasation. <i>Phytomedicine</i> , 2015, 22, 862-874.	5.3	9
21	Lobatin B inhibits NPM/ALK and NF- $\kappa$ B attenuating anaplastic-large-cell-lymphomagenesis and lymphendothelial tumour intravasation. <i>Cancer Letters</i> , 2015, 356, 994-1006.	7.2	8
22	Resveratrol and its major sulfated conjugates are substrates of organic anion transporting polypeptides (OATPs): Impact on growth of ZR $\hat{c}$ 75 breast cancer cells. <i>Molecular Nutrition and Food Research</i> , 2014, 58, 1830-1842.	3.3	38
23	In vitro characterisation of the anti-intravasative properties of the marine product heteronemin. <i>Archives of Toxicology</i> , 2013, 87, 1851-1861.	4.2	26
24	Xanthohumol attenuates tumour cell-mediated breaching of the lymphendothelial barrier and prevents intravasation and metastasis. <i>Archives of Toxicology</i> , 2013, 87, 1301-1312.	4.2	41
25	Methyl-2-arylidene hydrazinocarbothioates: synthesis and biological activity. <i>Chemical Papers</i> , 2013, 67, 650-656.	2.2	10
26	Synthesis antimicrobial and anticancer activity of N $\hat{c}$ 2-arylmethylidene-piperazine-1-carbothiohydrazide. <i>Medicinal Chemistry Research</i> , 2013, 22, 2802-2808.	2.4	10
27	Inhibition of tumour spheroid-induced prometastatic intravasation gates in the lymph endothelial cell barrier by carbamazepine: drug testing in a 3D model. <i>Archives of Toxicology</i> , 2013, 88, 691-9.	4.2	24
28	Interplay between metabolism and transport of resveratrol. <i>Annals of the New York Academy of Sciences</i> , 2013, 1290, 98-106.	3.8	39
29	Formation of micronuclei and other nuclear anomalies in exfoliated nasal and oral cells: Results of a human study with workers in a power plant processing poultry litter. <i>International Journal of Hygiene and Environmental Health</i> , 2013, 216, 82-87.	4.3	20
30	cobas 8000 Modular Analyzer Series Evaluated under Routine-like Conditions at 14 Sites in Australia, Europe, and the United States. <i>Journal of the Association for Laboratory Automation</i> , 2013, 18, 306-327.	2.8	24
31	Digalloylresveratrol, a novel resveratrol analog inhibits the growth of human pancreatic cancer cells. <i>Investigational New Drugs</i> , 2013, 31, 1115-1124.	2.6	14
32	Fractionation of an Extract of <i>Pluchea odorata</i> Separates a Property Indicative for the Induction of Cell Plasticity from One That Inhibits a Neoplastic Phenotype. <i>Evidence-based Complementary and Alternative Medicine</i> , 2012, 2012, 1-11.	1.2	6
33	Performance Evaluation of the Sysmex XE-5000 Hematology Analyzer for White Blood Cell Analysis in Cerebrospinal Fluid. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 194-198.	2.5	29
34	Hsp90 stabilizes Cdc25A and counteracts heat shock-mediated Cdc25A degradation and cell-cycle attenuation in pancreatic carcinoma cells. <i>Human Molecular Genetics</i> , 2012, 21, 4615-4627.	2.9	8
35	The EC4 European Syllabus for Post-Graduate Training in Clinical Chemistry and Laboratory Medicine: version 4 $\hat{c}$ 2012. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 1317-28.	2.3	23
36	An apolar extract of <i>Critonia morifolia</i> inhibits c-Myc, cyclin D1, Cdc25A, Cdc25B, Cdc25C and Akt and induces apoptosis. <i>International Journal of Oncology</i> , 2012, 40, 2131-9.	3.3	3

#	ARTICLE	IF	CITATIONS
37	Methanol extract of the ethnopharmaceutical remedy <i>Smilax spinosa</i> exhibits anti-neoplastic activity. <i>International Journal of Oncology</i> , 2012, 41, 1164-1172.	3.3	30
38	Effect of substitution at N <sup>3</sup> -position of N <sup>2</sup> -hydroxy-N-amino guanidines on tumor cell growth. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 4934-4938.	2.2	3
39	Inorganic phosphate and FGF <sup>23</sup> predict outcome in stable systolic heart failure. <i>European Journal of Clinical Investigation</i> , 2012, 42, 649-656.	3.4	64
40	Metabolomic Analysis of Resveratrol-Induced Effects in the Human Breast Cancer Cell Lines MCF-7 and MDA-MB-231. <i>OMICS A Journal of Integrative Biology</i> , 2011, 15, 9-14.	2.0	34
41	Combination Effects of Digalloylresveratrol With Arabinofuranosylcytosine and Difluorodeoxycytidine in Human Leukemia and Pancreatic Cancer Cells. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2011, 30, 1190-1196.	1.1	2
42	Antiproliferative effects of some novel synthetic solanidine analogs on HL-60 human leukemia cells in vitro. <i>Steroids</i> , 2011, 76, 156-162.	1.8	35
43	Histone deacetylase inhibition modulates deoxyribonucleotide pools and enhances the antitumor effects of the ribonucleotide reductase inhibitor 3'-C-methyladenosine in leukaemia cells. <i>International Journal of Oncology</i> , 2011, 38, 1427-36.	3.3	7
44	Chemopreventive effects of resveratrol and resveratrol derivatives. <i>Annals of the New York Academy of Sciences</i> , 2011, 1215, 89-95.	3.8	93
45	A novel N-hydroxy-N <sup>2</sup> -aminoguanidine derivative inhibits ribonucleotide reductase activity: Effects in human HL-60 promyelocytic leukemia cells and synergism with arabinofuranosylcytosine (Ara-C). <i>Biochemical Pharmacology</i> , 2011, 81, 50-59.	4.4	12
46	Impact of spinach consumption on DNA stability in peripheral lymphocytes and on biochemical blood parameters: results of a human intervention trial. <i>European Journal of Nutrition</i> , 2011, 50, 587-594.	3.9	18
47	N-Hydroxy-N <sup>2</sup> -aminoguanidines as anti-cancer lead molecule: QSAR, synthesis and biological evaluation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 3324-3328.	2.2	17
48	Hepatic Glucuronidation of Resveratrol: Interspecies Comparison of Enzyme Kinetic Profiles in Human, Mouse, Rat, and Dog. <i>Drug Metabolism and Pharmacokinetics</i> , 2011, 26, 364-373.	2.2	44
49	What Is New for an Old Molecule? Systematic Review and Recommendations on the Use of Resveratrol. <i>PLoS ONE</i> , 2011, 6, e19881.	2.5	375
50	Separation of anti-neoplastic activities by fractionation of a <i>Pluchea odorata</i> extract. <i>Frontiers in Bioscience - Elite</i> , 2011, E3, 1326-1336.	1.8	3
51	In-vitro sulfation of piceatannol by human liver cytosol and recombinant sulfotransferases. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 61, 185-191.	2.4	18
52	Glucuronidation of piceatannol by human liver microsomes: major role of UGT1A1, UGT1A8 and UGT1A10. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 62, 47-54.	2.4	27
53	Resveratrol and Resveratrol Analogues' Structure' Activity Relationship. <i>Pharmaceutical Research</i> , 2010, 27, 1042-1048.	3.5	100
54	In vitro anti-leukemic activity of the ethno-pharmacological plant <i>Scutellaria orientalis</i> ssp. <i>carica</i> endemic to western Turkey. <i>Phytomedicine</i> , 2010, 17, 55-62.	5.3	39

#	ARTICLE	IF	CITATIONS
55	Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 3906-3910.	2.2	45
56	Multifactorial anticancer effects of digalloyl-resveratrol encompass apoptosis, cell-cycle arrest, and inhibition of lymphendothelial gap formation in vitro. <i>British Journal of Cancer</i> , 2010, 102, 1361-1370.	6.4	45
57	The European Register of Specialists in Clinical Chemistry and Laboratory Medicine: Guide to the Register, Version 3-2010. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 999-1008.	2.3	17
58	Pro- and anticarcinogenic mechanisms of piceatannol are activated dose dependently in MCF-7 breast cancer cells. <i>Carcinogenesis</i> , 2010, 31, 2074-2081.	2.8	24
59	3,3,4,4,5,5-Hexahydroxystilbene Impairs Melanoma Progression in a Metastatic Mouse Model. <i>Journal of Investigative Dermatology</i> , 2010, 130, 1668-1679.	0.7	29
60	Expression of sulfotransferases and sulfatases in human breast cancer: Impact on resveratrol metabolism. <i>Cancer Letters</i> , 2010, 289, 237-245.	7.2	36
61	Antitumor Activity of Resveratrol and its Sulfated Metabolites against Human Breast Cancer Cells. <i>Planta Medica</i> , 2009, 75, 1227-1230.	1.3	66
62	Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells. <i>Investigational New Drugs</i> , 2009, 27, 393-401.	2.6	27
63	NT-proBNP is increased in healthy pregnancies compared to non-pregnant controls. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2009, 88, 234-237.	2.8	40
64	Digalloylresveratrol, a new phenolic acid derivative induces apoptosis and cell cycle arrest in human HT-29 colon cancer cells. <i>Cancer Letters</i> , 2009, 274, 299-304.	7.2	36
65	In vitro anti-cancer activity of two ethno-pharmacological healing plants from Guatemala <i>Pluchea odorata</i> and <i>Phlebodium decumanum</i> . <i>International Journal of Oncology</i> , 2009, 34, 1117-28.	3.3	15
66	In vitro anti-neoplastic activity of the ethno-pharmaceutical plant <i>Hypericum adenotrichum</i> Spach endemic to Western Turkey. <i>Oncology Reports</i> , 2009, 22, 845-52.	2.6	11
67	A polar extract of the Maya healing plant <i>Anthurium schlechtendalii</i> (Aracea) exhibits strong in vitro anticancer activity. <i>International Journal of Molecular Medicine</i> , 2009, 24, 513-21.	4.0	3
68	In-vitro sulfation of piceatannol by human liver cytosol and recombinant sulfotransferases. <i>Journal of Pharmacy and Pharmacology</i> , 2009, 61, 185-191.	2.4	9
69	Synthesis and cytotoxic activity of resveratrol-based compounds. <i>Monatshefte für Chemie</i> , 2008, 139, 575-578.	1.8	3
70	Metabolism and Disposition of Resveratrol in the Isolated Perfused Rat Liver: Role of Mrp2 in the Biliary Excretion of Glucuronides. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 1615-1628.	3.3	50
71	Resveratrol and its analogs: Defense against cancer, coronary disease and neurodegenerative maladies or just a fad?. <i>Mutation Research - Reviews in Mutation Research</i> , 2008, 658, 68-94.	5.5	383
72	Cytotoxic activity of 3,3,4,4,5,5-hexahydroxystilbene against breast cancer cells is mediated by induction of p53 and downregulation of mitochondrial superoxide dismutase. <i>Toxicology in Vitro</i> , 2008, 22, 1361-1370.	2.4	44

#	ARTICLE	IF	CITATIONS
73	Synergistic effects of deuterium oxide and gemcitabine in human pancreatic cancer cell lines. <i>Cancer Letters</i> , 2008, 259, 231-239.	7.2	16
74	Metabolism of resveratrol in breast cancer cell lines: Impact of sulfotransferase 1A1 expression on cell growth inhibition. <i>Cancer Letters</i> , 2008, 261, 172-182.	7.2	57
75	Ribose-Modified Purine Nucleosides as Ribonucleotide Reductase Inhibitors. Synthesis, Antitumor Activity, and Molecular Modeling of <sup>6</sup> -Substituted 3- <i>C</i> -Methyladenosine Derivatives. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 4260-4269.	6.4	20
76	Novel resveratrol analogs induce apoptosis and cause cell cycle arrest in HT29 human colon cancer cells: Inhibition of ribonucleotide reductase activity. <i>Oncology Reports</i> , 2008, , .	2.6	12
77	Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body's red cell volume. <i>European Heart Journal</i> , 2008, 29, 2343-2350.	2.2	113
78	Stilbene analogues affect cell cycle progression and apoptosis independently of each other in an MCF-7 array of clones with distinct genetic and chemoresistant backgrounds. <i>Oncology Reports</i> , 2008, 19, 801-10.	2.6	17
79	Novel resveratrol analogs induce apoptosis and cause cell cycle arrest in HT29 human colon cancer cells: inhibition of ribonucleotide reductase activity. <i>Oncology Reports</i> , 2008, 19, 1621-6.	2.6	27
80	Biochemical effects of piceatannol in human HL-60 promyelocytic leukemia cells--synergism with Ara-C. <i>International Journal of Oncology</i> , 2008, 33, 887-92.	3.3	2
81	Effects of neuromuscular electrical stimulation of the knee extensor muscles on muscle soreness and different serum parameters in young male athletes: preliminary data. <i>British Journal of Sports Medicine</i> , 2007, 41, 914-916.	6.7	7
82	N-terminal pro-B-type natriuretic peptide is an independent predictor of outcome in an unselected cohort of critically ill patients*. <i>Critical Care Medicine</i> , 2007, 35, 2268-2273.	0.9	85
83	Gallic acid inhibits ribonucleotide reductase and cyclooxygenases in human HL-60 promyelocytic leukemia cells. <i>Cancer Letters</i> , 2007, 245, 156-162.	7.2	123
84	Avemar, a nontoxic fermented wheat germ extract, induces apoptosis and inhibits ribonucleotide reductase in human HL-60 promyelocytic leukemia cells. <i>Cancer Letters</i> , 2007, 250, 323-328.	7.2	23
85	N-hydroxy-N'-(3,4,5-trimethoxyphenyl)-3,4,5-trimethoxy-benzamidine, a novel resveratrol analog, inhibits ribonucleotide reductase in HL-60 human promyelocytic leukemia cells: Synergistic antitumor activity with arabinofuranosylcytosine. <i>International Journal of Oncology</i> , 2007, , .	3.3	5
86	N-hydroxy-N'-(3,4,5-trimethoxyphenyl)-3,4,5-trimethoxy-benzamidine, a novel resveratrol analog, inhibits ribonucleotide reductase in HL-60 human promyelocytic leukemia cells: synergistic antitumor activity with arabinofuranosylcytosine. <i>International Journal of Oncology</i> , 2007, 31, 1261-6.	3.3	6
87	Novel resveratrol derivatives induce apoptosis and cause cell cycle arrest in prostate cancer cell lines. <i>Anticancer Research</i> , 2007, 27, 3459-64.	1.1	37
88	Potential of the activity of cisplatin and cyclophosphamide by trimidox, a novel ribonucleotide reductase inhibitor, in leukemia-bearing mice. <i>Cancer Letters</i> , 2006, 233, 178-184.	7.2	6
89	Antioxidant activity of resveratrol, piceatannol and 3,3',4,4',5,5'-hexahydroxy-trans-stilbene in three leukemia cell lines. <i>Oncology Reports</i> , 2006, 16, 617.	2.6	31
90	5-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC-resistant MCF-7 breast cancer cells overexpressing ErbB2. <i>Differentiation</i> , 2006, 74, 488-498.	1.9	17

#	ARTICLE	IF	CITATIONS
91	Increased Transport of Resveratrol Across Monolayers of the Human Intestinal Caco-2 Cells is Mediated by Inhibition and Saturation of Metabolites. <i>Pharmaceutical Research</i> , 2006, 23, 2107-2115.	3.5	85
92	Analysis of mechanisms contributing to AraC-mediated chemoresistance and re-establishment of drug sensitivity by the novel heterodinucleoside phosphate 5-FdUrd-araC. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2006, 11, 427-440.	4.9	16
93	Cytotoxic and biochemical effects of 3,3',4,4',5,5'-hexahydroxystilbene, a novel resveratrol analog in HL-60 human promyelocytic leukemia cells. <i>Experimental Hematology</i> , 2006, 34, 1377-1384.	0.4	43
94	EC4 European Syllabus for Post-Graduate Training in Clinical Chemistry and Laboratory Medicine: version 3 – 2005. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006, 44, 110-20.	2.3	19
95	Antioxidant activity of resveratrol, piceatannol and 3,3',4,4',5,5'-hexahydroxy-trans-stilbene in three leukemia cell lines. <i>Oncology Reports</i> , 2006, 16, 617-24.	2.6	65
96	Immunologic and Biochemical Effects of the Fermented Wheat Germ Extract Avemar. <i>Experimental Biology and Medicine</i> , 2005, 230, 144-149.	2.4	28
97	Cytotoxic effects of novel amphiphilic dimers consisting of 5-fluorodeoxyuridine and arabinofuranosylcytosine in cross-resistant H9 human lymphoma cells. <i>Leukemia Research</i> , 2005, 29, 785-791.	0.8	8
98	Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship. <i>Biochemical Pharmacology</i> , 2005, 69, 903-912.	4.4	272
99	Synergistic action of resveratrol, an ingredient of wine, with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells. <i>Experimental Hematology</i> , 2005, 33, 329-335.	0.4	42
100	Recent developments in cancer chemotherapy oriented towards new targets. <i>Expert Opinion on Therapeutic Targets</i> , 2005, 9, 343-357.	3.4	2
101	Antitumor Activity of C-Methyl- <sup>2</sup> -d-ribofuranosyladenine Nucleoside Ribonucleotide Reductase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 4983-4989.	6.4	35
102	Clinical pharmacogenetics of immunosuppressive drugs in organ transplantation. <i>Pharmacogenomics</i> , 2005, 6, 163-168.	1.3	22
103	Effects of heavy water (D2O) on human pancreatic tumor cells. <i>Anticancer Research</i> , 2005, 25, 3407-11.	1.1	28
104	Cytotoxic and Apoptotic Effects of Novel Heterodinucleoside Phosphates Consisting of 5-Fluorodeoxyuridine and Ara-C in Human Cancer Cell Lines. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2004, 23, 1507-1511.	1.1	1
105	Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 5571-5578.	3.0	262
106	Combination Chemotherapy of BCNU and Didox Acts Synergistically in 9L Glioma Cells. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2004, 23, 1531-1535.	1.1	10
107	Biochemical modulation of Ara-C effects by amidox, an inhibitor of ribonucleotide reductase in HL-60 promyelocytic human leukemia cells. <i>Life Sciences</i> , 2004, 74, 1071-1080.	4.3	0
108	Studies with Benzamide Riboside, a Recent Inhibitor of Inosine 5'-Monophosphate Dehydrogenase. <i>ACS Symposium Series</i> , 2003, , 231-246.	0.5	1

#	ARTICLE	IF	CITATIONS
109	Four-year study of cobalt and chromium blood levels in patients managed with two different metal-on-metal total hip replacements. <i>Journal of Orthopaedic Research</i> , 2003, 21, 189-195.	2.3	209
110	Cancer Therapy: New Targets for Chemotherapy. <i>Hematology</i> , 2003, 8, 129-137.	1.5	16
111	Benzamide Riboside, a Recent Inhibitor of Inosine 5-Monophosphate Dehydrogenase Induces Transferrin Receptors in Cancer Cells. <i>Current Medicinal Chemistry</i> , 2002, 9, 759-764.	2.4	24
112	New Targets and Drugs in Cancer Chemotherapy. <i>Medical Principles and Practice</i> , 2002, 11, 117-125.	2.4	9
113	Trimidox, an inhibitor of ribonucleotide reductase, synergistically enhances the inhibition of colony formation by Ara-C in HL-60 human promyelocytic leukemia cells. <i>Biochemical Pharmacology</i> , 2002, 64, 481-485.	4.4	23
114	Metabolism and disposition of the novel antileukaemic drug, benzamide riboside, in the isolated perfused rat liver. <i>Life Sciences</i> , 2001, 69, 2489-2502.	4.3	4
115	Antitumor activity of benzamide riboside and its combination with cisplatin and staurosporine. <i>European Journal of Pharmaceutical Sciences</i> , 2001, 12, 387-394.	4.0	21
116	Trimidox, an inhibitor of ribonucleotide reductase, induces apoptosis and activates caspases in HL-60 promyelocytic leukemia cells. <i>Experimental Hematology</i> , 2000, 28, 924-930.	0.4	27
117	Cyclosporine Metabolism in Patients After Kidney, Bone Marrow, Heart-Lung, and Liver Transplantation in the Early and Late Posttransplant Periods. <i>American Journal of Clinical Pathology</i> , 2000, 114, 536-543.	0.7	24
118	The ribonucleotide reductase inhibitor trimidox induces c-myc and apoptosis of human ovarian carcinoma cells. <i>Life Sciences</i> , 2000, 67, 3131-3142.	4.3	18
119	Sensitizing human colon carcinoma HT-29 cells to cisplatin by cyclopentenylcytosine, in vitro and in vivo. <i>Life Sciences</i> , 2000, 68, 1-11.	4.3	16
120	Emerging therapeutic targets in antiviral and anticancer therapy: a role for ribonucleotide reductase. <i>Expert Opinion on Therapeutic Targets</i> , 1999, 3, 251-261.	1.0	0
121	Benzamide riboside induces apoptosis independent of Cdc25A expression in human ovarian carcinoma N.1 cells. <i>Cell Death and Differentiation</i> , 1999, 6, 736-744.	11.2	23
122	Evaluation of Four Automated Methods for Determination of Whole Blood Cyclosporine Concentrations. <i>American Journal of Clinical Pathology</i> , 1999, 112, 358-365.	0.7	37
123	Enhanced effects of adriamycin by combination with a new ribonucleotide reductase inhibitor, trimidox, in murine leukemia. <i>Life Sciences</i> , 1998, 63, 545-552.	4.3	16
124	Studies on the antitumor activity and biochemical actions of cyclopentenyl cytosine against human colon carcinoma HT-29 in vitro and in vivo. <i>Life Sciences</i> , 1998, 64, 103-112.	4.3	20
125	Are allergic reactions to skin clips associated with delayed wound healing?. <i>American Journal of Surgery</i> , 1998, 176, 320-323.	1.8	48
126	The Enzyme Ribonucleotide Reductase: Target for Antitumor and Anti-HIV Therapy. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 1997, 34, 503-528.	6.1	78



#	ARTICLE	IF	CITATIONS
127	Iron binding capacity of didox (3,4-dihydroxybenzohydroxamic acid) and amidox (3,4-dihydroxybenzamidoxime) new inhibitors of the enzyme ribonucleotide reductase. Life Sciences, 1997, 61, 2231-2237.	4.3	10
128	Simultaneous determination of the new anticancer agent amidox and its metabolites in rat bile and plasma by high-performance liquid chromatography. Biomedical Applications, 1997, 696, 267-274.	1.7	1
129	The new inhibitors of ribonucleotide reductase—comparison of some physico-chemical properties. Journal of Pharmaceutical and Biomedical Analysis, 1997, 15, 951-956.	2.8	1
130	Cytotoxic effects of a doxorubicin-transferrin conjugate in multidrug-resistant KB cells. Biochemical Pharmacology, 1996, 51, 489-493.	4.4	40
131	Iron Binding Capacity of Trimidox (3,4,5-Trihydroxybenzamidoxime), a New Inhibitor of the Enzyme Ribonucleotide Reductase. Clinical Chemistry and Laboratory Medicine, 1995, 33, 785-9.	2.3	8
132	Sodium butyrate inhibits c-myc splicing and interferes with signal transduction in ovarian carcinoma cells. Carcinogenesis, 1995, 16, 1199-1205.	2.8	41
133	Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase. Cancer Chemotherapy and Pharmacology, 1994, 34, 63-66.	2.3	62
134	Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin. Biochemical Pharmacology, 1994, 48, 1413-1419.	4.4	37
135	Cytotoxicity, differentiating activity and metabolism of tiazofurin in human neuroblastoma cells. International Journal of Cancer, 1993, 55, 92-95.	5.1	11
136	GM-CSF: modulation of biochemical and cytotoxic effects of tiazofurin in HL-60 cells. British Journal of Haematology, 1993, 84, 552-554.	2.5	2
137	Synergistic action of tiazofurin with hypoxanthine and allopurinol in human neuroectodermal tumor cell lines. Biochemical Pharmacology, 1993, 46, 1903-1907.	4.4	4
138	Regulation of deoxycytidine kinase activity and inhibition by DFDC. Advances in Enzyme Regulation, 1993, 33, 39-59.	2.6	9
139	Cell cycle dependent regulation of IMP dehydrogenase activity and effect of tiazofurin. Life Sciences, 1992, 51, 1309-1315.	4.3	22
140	Cytotoxicity of a transferrin-adriamycin conjugate to anthracycline-resistant cells. International Journal of Cancer, 1992, 52, 619-623.	5.1	37
141	AZT: A Biochemical Response Modifier of Methotrexate and 5-Fluorouracil Cytotoxicity in Human Ovarian and Pancreatic Carcinoma Cells. European Journal of Implant and Refractive Surgery, 1991, 3, 127-132.	0.3	27